Mizuho analyst Graig Suvannavejh reiterated a Neutral rating and $3.50 price target on Corvus Pharmaceuticals (NASDAQ: CRVS)The analyst comments "CRVS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE